Bioventus Inc(NASDAQ:BVS) 
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, incl...
Website: http://www.bioventusglobal.com
Founded: 2011
Sector: Healthcare
Industry: Diagnostics & Research
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-28 | 2025-12-31 | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | 2024-06-29 | 2024-03-30 | 2023-12-31 | 2023-09-30 | 2023-07-01 | 2023-04-01 | 2022-12-31 | 2022-10-01 | 2022-07-02 | 2022-04-02 | 2021-12-31 | 2021-10-02 | 2021-07-03 | 2021-04-03 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net sales | 132,089,000 | 157,900,000 | 138,651,000 | 147,660,000 | 123,876,000 | 153,642,000 | 138,964,000 | 151,217,000 | 129,457,000 | 135,423,000 | 120,794,000 | 137,069,000 | 119,059,000 | 125,834,000 | 128,662,000 | 140,331,000 | 117,290,000 | 130,414,000 | 108,890,000 | 109,816,000 | 81,778,000 | |
yoy | 6.63% | 2.77% | -0.23% | -2.35% | -4.31% | 13.45% | 15.04% | 10.32% | 8.73% | 7.62% | -6.12% | -2.32% | 1.51% | -3.51% | 18.16% | 27.79% | 43.42% | |||||
qoq | -16.35% | 13.88% | -6.10% | 19.20% | -19.37% | 10.56% | -8.10% | 16.81% | -4.41% | 12.11% | -11.87% | 15.13% | -5.38% | -2.20% | -8.32% | 19.64% | -10.06% | 19.77% | -0.84% | 34.29% | ||
cost of sales | 41,320,000 | 49,118,000 | 44,422,000 | 45,570,000 | 40,820,000 | 50,986,000 | 45,413,000 | 47,578,000 | 41,077,000 | 49,122,000 | 41,944,000 | 47,946,000 | 45,140,000 | 51,645,000 | 44,127,000 | 43,677,000 | 41,588,000 | 42,646,000 | 29,821,000 | 33,503,000 | 22,222,000 | |
gross profit | 90,769,000 | 108,782,000 | 94,229,000 | 102,090,000 | 83,056,000 | 102,656,000 | 93,551,000 | 103,639,000 | 88,380,000 | 86,301,000 | 78,850,000 | 89,123,000 | 73,919,000 | 74,189,000 | 84,535,000 | 96,654,000 | 75,702,000 | 87,768,000 | 79,069,000 | 76,313,000 | 59,556,000 | |
yoy | 9.29% | 5.97% | 0.72% | -1.49% | -6.02% | 18.95% | 18.64% | 16.29% | 19.56% | 16.33% | -6.73% | -7.79% | -2.36% | -15.47% | 6.91% | 26.65% | 27.11% | |||||
qoq | -16.56% | 15.44% | -7.70% | 22.92% | -19.09% | 9.73% | -9.73% | 17.27% | 2.41% | 9.45% | -11.53% | 20.57% | -0.36% | -12.24% | -12.54% | 27.68% | -13.75% | 11.00% | 3.61% | 28.14% | ||
gross margin % | 68.72% | 68.89% | 67.96% | 69.14% | 67.05% | 66.82% | 67.32% | 68.54% | 68.27% | 63.73% | 65.28% | 65.02% | 62.09% | 58.96% | 65.70% | 68.88% | 64.54% | 67.30% | 72.61% | 69.49% | 72.83% | |
selling, general and administrative expense | 78,325,000 | 82,757,000 | 78,657,000 | 79,110,000 | 73,502,000 | 86,613,000 | 81,090,000 | 94,785,000 | 78,406,000 | 78,357,000 | 69,820,000 | 74,844,000 | 80,858,000 | 77,668,000 | 79,194,000 | 89,620,000 | 86,124,000 | 80,881,000 | 69,636,000 | 69,050,000 | 34,686,000 | |
research and development expense | 2,467,000 | 3,007,000 | 2,923,000 | 3,172,000 | 3,011,000 | 3,246,000 | 3,808,000 | 3,988,000 | 2,597,000 | 3,262,000 | 3,015,000 | 3,398,000 | 3,771,000 | 6,807,000 | 5,840,000 | 6,366,000 | 6,928,000 | 7,103,000 | 6,153,000 | 4,836,000 | 947,000 | |
restructuring costs | 454,000 | -71,000 | -26,000 | 620,000 | 317,000 | 4,620,000 | 575,000 | 1,007,000 | 577,000 | 689,000 | 1,798,000 | |||||||||||
depreciation and amortization | 1,107,000 | 1,297,000 | 1,398,000 | 1,439,000 | 1,593,000 | 1,768,000 | 2,065,000 | 2,064,000 | 1,755,000 | 2,102,000 | 2,317,000 | 2,294,000 | 2,129,000 | 7,761,000 | 7,442,000 | 2,696,000 | 3,254,000 | 2,708,000 | 1,878,000 | 1,852,000 | 1,925,000 | |
loss on disposals | -1,000 | 1,000 | 81,000 | 1,196,000 | 1,404,000 | |||||||||||||||||
operating income | 8,416,000 | 19,486,000 | 11,252,000 | 18,368,000 | 4,869,000 | 7,988,000 | 4,074,000 | -29,368,000 | 5,327,000 | 1,165,000 | 2,418,000 | 6,750,000 | -92,058,000 | -25,435,000 | -200,855,000 | -3,308,000 | -21,450,000 | -3,150,000 | -1,047,000 | -5,740,000 | 21,998,000 | |
yoy | 72.85% | 143.94% | 176.19% | -162.54% | -8.60% | 585.67% | 68.49% | -535.08% | -105.79% | -104.58% | -101.20% | -304.05% | 329.17% | 707.46% | 19083.86% | -42.37% | -197.51% | |||||
qoq | -56.81% | 73.18% | -38.74% | 277.24% | -39.05% | 96.07% | -113.87% | -651.30% | 357.25% | -51.82% | -64.18% | -107.33% | 261.93% | -87.34% | 5971.80% | -84.58% | 580.95% | 200.86% | -81.76% | -126.09% | ||
operating margin % | 6.37% | 12.34% | 8.12% | 12.44% | 3.93% | 5.20% | 2.93% | -19.42% | 4.11% | 0.86% | 2.00% | 4.92% | -77.32% | -20.21% | -156.11% | -2.36% | -18.29% | -2.42% | -0.96% | -5.23% | 26.90% | |
interest expense | 4,326,000 | 5,306,000 | 6,177,000 | 7,494,000 | 7,509,000 | 8,997,000 | 9,532,000 | 9,924,000 | 10,339,000 | 10,280,000 | 10,115,000 | 10,587,000 | 9,694,000 | 14,873,000 | 9,894,000 | 2,578,000 | 960,000 | 1,347,000 | 1,681,000 | -2,876,000 | ||
other expense | -427,000 | 37,000 | 79,000 | 561,000 | 777,000 | -1,241,000 | -626,000 | 159,000 | 63,000 | -709,000 | 494,000 | 513,000 | 8,106,000 | 9,406,000 | -23,272,000 | 884,000 | 38,000 | 508,000 | 757,000 | 1,645,000 | 419,000 | |
income before income taxes | 4,517,000 | 14,143,000 | 4,670,000 | 10,313,000 | -3,417,000 | 232,000 | -4,832,000 | -39,451,000 | -5,075,000 | -8,406,000 | -8,191,000 | -4,350,000 | -100,164,000 | -49,714,000 | -187,477,000 | -6,770,000 | -19,938,000 | 3,059,500 | -3,151,000 | -9,066,000 | 24,455,000 | |
income tax expense | 571,000 | -3,175,000 | 664,000 | 1,041,000 | -95,000 | 550,000 | 589,000 | -7,339,000 | 907,000 | -750,000 | 600,000 | 381,000 | -4,841,000 | -41,779,000 | 1,244,000 | -2,725,000 | -882,000 | 1,714,000 | -73,000 | |||
net income | 3,946,000 | 17,318,000 | 4,006,000 | 9,272,000 | -3,322,000 | -318,000 | -5,421,000 | -32,112,000 | -5,982,000 | -7,656,000 | -8,791,000 | -4,731,000 | -174,447,000 | -44,873,000 | -145,698,000 | -8,014,000 | -14,806,000 | -1,893,000 | -2,269,000 | -10,780,000 | 24,528,000 | |
yoy | -218.78% | -5545.91% | -173.90% | -128.87% | -44.47% | -95.85% | -38.33% | 578.76% | -96.57% | -82.94% | -93.97% | -40.97% | 1078.22% | 2270.47% | 6321.24% | -25.66% | -160.36% | |||||
qoq | -77.21% | 332.30% | -56.79% | -379.11% | 944.65% | -94.13% | -83.12% | 436.81% | -21.87% | -12.91% | 85.82% | -97.29% | 288.76% | -69.20% | 1718.04% | -45.87% | 682.14% | -16.57% | -78.95% | -143.95% | ||
net income margin % | 2.99% | 10.97% | 2.89% | 6.28% | -2.68% | -0.21% | -3.90% | -21.24% | -4.62% | -5.65% | -7.28% | -3.45% | -146.52% | -35.66% | -113.24% | -5.71% | -12.62% | -1.45% | -2.08% | -9.82% | 29.99% | |
loss attributable to noncontrolling interest | -833,000 | -494,750 | -851,000 | -1,813,000 | 685,000 | 12,943,000 | 37,453,000 | 762,000 | 3,529,000 | 1,529,000 | 1,198,000 | 6,654,000 | 408,000 | |||||||||
net income attributable to bioventus inc. | 3,113,000 | 14,755,000 | 3,155,000 | 7,459,000 | -31,930,000 | -108,245,000 | -7,252,000 | -11,277,000 | -364,000 | -1,071,000 | -4,126,000 | 24,936,000 | ||||||||||
other comprehensive income, net of tax | ||||||||||||||||||||||
change in foreign currency translation adjustments | -1,468,000 | 108,000 | -528,000 | 1,593,000 | 633,000 | -3,758,000 | 575,000 | -426,000 | -585,000 | 504,000 | -324,000 | 303,000 | 657,000 | 1,411,000 | -723,000 | -507,000 | -682,000 | -93,000 | -366,000 | 23,000 | -1,156,000 | |
change in the fair value of cash flow hedges | 1,000,000 | -206,000 | -785,000 | |||||||||||||||||||
comprehensive income | 3,478,000 | 17,241,000 | 2,693,000 | 10,865,000 | -8,521,000 | -15,488,000 | -1,926,000 | -2,635,000 | -10,757,000 | 23,780,000 | ||||||||||||
comprehensive loss attributable to noncontrolling interest | -744,000 | -539,000 | -601,000 | 563,000 | 12,629,000 | 37,600,000 | 868,000 | 3,669,000 | 1,607,000 | 1,300,000 | 6,648,000 | |||||||||||
comprehensive income attributable to bioventus inc. | 2,734,000 | 14,692,000 | 2,092,000 | 8,747,000 | -30,700,000 | -108,821,000 | -7,653,000 | -11,819,000 | -319,000 | -1,335,000 | -4,109,000 | |||||||||||
income per share of class a common stock: | ||||||||||||||||||||||
basic | 0.05 | 0.03 | 0.05 | 0.11 | ||||||||||||||||||
diluted | 0.04 | 0.03 | 0.05 | 0.11 | ||||||||||||||||||
weighted-average shares of class a common stock outstanding: | ||||||||||||||||||||||
basic | 67,296,336 | 66,622,631 | 66,924,682 | 66,500,433 | ||||||||||||||||||
diluted | 70,008,291 | 68,914,895 | 68,837,797 | 68,536,759 | ||||||||||||||||||
change in fair value of contingent consideration | 345,000 | 483,000 | 300,000 | 295,000 | 290,000 | -98,000 | 240,000 | 287,000 | 2,768,000 | 3,142,000 | 273,000 | 269,000 | -463,000 | 651,000 | 641,000 | |||||||
impairment of assets | 78,615,000 | |||||||||||||||||||||
loss on extinguishment | 326,000 | |||||||||||||||||||||
comprehensive income attributable to noncontrolling interest | -2,118,000 | |||||||||||||||||||||
net loss attributable to bioventus inc. | -2,637,000 | -156,000 | -4,824,000 | -23,992,000 | -4,570,000 | -37,533,500 | -7,303,000 | -3,681,000 | -139,150,000 | |||||||||||||
comprehensive loss | -2,689,000 | -4,063,000 | -4,846,000 | -32,538,000 | -6,567,000 | -28,226,000 | -9,115,000 | -4,428,000 | -99,361,000 | -42,607,500 | -146,421,000 | |||||||||||
comprehensive loss attributable to bioventus inc. | -2,126,000 | -3,174,000 | -4,362,000 | -24,334,000 | -5,039,000 | -18,799,500 | -7,561,000 | -3,439,000 | -64,198,000 | |||||||||||||
loss per share of class a common stock, basic and diluted: | -0.04 | -0.52 | -1.76 | -0.11 | -0.19 | -0.03 | -0.1 | -0.02 | ||||||||||||||
weighted-average shares of class a common stock outstanding, basic and diluted: | 66,008,683 | 64,547,474 | 65,258,427 | 64,056,759 | 63,380,187 | 62,647,554 | 62,824,318 | 62,551,285 | 62,124,752 | 61,389,107 | 61,674,254 | 61,475,350 | 60,484,969 | 45,472,483 | 41,837,581 | 41,805,347 | 41,797,882 | |||||
impairments of assets | 8,475,250 | 2,031,000 | 31,870,000 | 19,653,750 | ||||||||||||||||||
net income from continuing operations | -318,000 | -5,421,000 | -32,112,000 | -5,982,000 | -7,656,000 | -8,791,000 | -4,731,000 | -100,018,000 | ||||||||||||||
loss from discontinued operations, net of tax | -74,429,000 | |||||||||||||||||||||
loss attributable to noncontrolling interest - continuing operations | 162,000 | 597,000 | 8,120,000 | 1,412,000 | 1,560,000 | 1,488,000 | 1,050,000 | 20,360,000 | ||||||||||||||
loss attributable to noncontrolling interest - discontinued operations | 14,937,000 | |||||||||||||||||||||
comprehensive loss attributable to noncontrolling interest - continuing operations | 889,000 | 484,000 | 8,204,000 | 1,528,000 | 1,461,000 | 1,554,000 | 989,000 | 20,226,000 | ||||||||||||||
comprehensive loss attributable to noncontrolling interest - discontinued operations | 14,937,000 | |||||||||||||||||||||
loss per share of class a common stock from continuing operations, basic and diluted: | -0.13 | -0.07 | -0.37 | -0.07 | -0.363 | -0.12 | -0.06 | -1.28 | ||||||||||||||
loss per share of class a common stock from discontinued operations, basic and diluted: | -0.238 | -0.96 | ||||||||||||||||||||
loss per share of class a common stock, basic and diluted | -0.07 | -0.37 | -0.07 | -0.09 | -0.12 | -0.06 | -2.24 | |||||||||||||||
loss on disposal of a business | 977,000 | |||||||||||||||||||||
other income | -1,588,000 | -1,512,000 | ||||||||||||||||||||
income tax benefit | -146,000 | -5,132,000 | ||||||||||||||||||||
other comprehensive loss, net of tax | ||||||||||||||||||||||
impairment of goodwill | 189,197,000 | |||||||||||||||||||||
impairment of variable interest entity assets | 5,674,000 | |||||||||||||||||||||
per share information for the nine months ended october 2, 2021 represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding from february 16, 2021 through october 2, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 8. earnings per share within the notes to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||
per share information for the six months ended july 2, 2021 represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding from february 16, 2021 through july 3, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 8. earnings per share within the notes to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||
interest income | -1,550,000 | |||||||||||||||||||||
per share information for the three months ended april 2, 2021 represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding from february 16, 2021 through october 2, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 8. earnings per share within the notes to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||
per share information for the nine months ended october 2, 2021 represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding from february 16, 2021 through october 2, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 7. earnings per share within the notes to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||
per share information for the six months ended july 3, 2021 represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding from february 16, 2021 through july 3, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 7. earnings per share within the notes to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||
represents loss per share of class a common stock and weighted-average shares of class a common stock outstanding for the period from february 16, 2021 through april 3, 2021, the period following bioventus inc.'s initial public offering and related transactions described in note 1. organization and note 7. earnings per share within the notes to the unaudited condensed consolidated financial statements. |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-28 | 2025-12-31 | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | 2024-06-29 | 2024-03-30 | 2023-12-31 | 2023-09-30 | 2023-07-01 | 2023-04-01 | 2022-12-31 | 2022-10-01 | 2022-07-02 | 2022-04-02 | 2021-12-31 | 2021-10-02 | 2021-07-03 | 2021-04-03 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||
current assets: | ||||||||||||||||||||||
cash and cash equivalents | 35,846,000 | 51,238,000 | 42,164,000 | 32,910,000 | 22,802,000 | 41,582,000 | 43,074,000 | 31,994,000 | 25,173,000 | 36,964,000 | 26,827,000 | 29,389,000 | 47,102,000 | 31,814,000 | 34,359,000 | 41,001,000 | 27,374,000 | 43,933,000 | 80,917,000 | 136,065,000 | 124,247,000 | 86,839,000 |
accounts receivable | 120,525,000 | 128,303,000 | 130,404,000 | 132,367,000 | 118,082,000 | 127,393,000 | 121,925,000 | 137,305,000 | 125,541,000 | 122,789,000 | 112,899,000 | 119,636,000 | 118,544,000 | 136,645,000 | 132,185,000 | 143,018,000 | 119,288,000 | 124,963,000 | 105,442,000 | 102,029,000 | 89,472,000 | 88,283,000 |
inventory | 83,187,000 | 82,236,000 | 96,273,000 | 96,465,000 | 94,045,000 | 92,475,000 | 90,032,000 | 87,606,000 | 97,005,000 | 91,333,000 | 97,563,000 | 96,276,000 | 87,953,000 | 85,408,000 | 76,952,000 | 69,078,000 | 64,691,000 | 61,688,000 | 36,565,000 | 34,020,000 | 39,808,000 | 29,120,000 |
prepaid and other current assets | 10,255,000 | 11,065,000 | 12,060,000 | 13,461,000 | 14,438,000 | 14,160,000 | 16,923,000 | 23,570,000 | 18,184,000 | 16,913,000 | 12,163,000 | 15,337,000 | 17,192,000 | 18,685,000 | 27,563,000 | 24,060,000 | 28,762,000 | 27,239,000 | 23,154,000 | 15,943,000 | 11,987,000 | 7,552,000 |
total current assets | 249,813,000 | 272,842,000 | 280,901,000 | 275,203,000 | 249,367,000 | 275,610,000 | 298,688,000 | 308,883,000 | 265,903,000 | 267,999,000 | 249,452,000 | 260,638,000 | 308,664,000 | 272,575,000 | 271,082,000 | 277,157,000 | 245,395,000 | 263,103,000 | 246,078,000 | 290,060,000 | 270,721,000 | 211,794,000 |
property and equipment | 21,294,000 | 21,899,000 | 22,983,000 | 24,512,000 | 25,722,000 | 27,012,000 | 29,425,000 | 31,938,000 | 34,532,000 | 36,605,000 | 39,704,000 | 41,862,000 | 36,556,000 | 27,647,000 | 26,643,000 | 25,112,000 | 24,856,000 | 22,985,000 | 10,297,000 | 8,960,000 | 8,084,000 | 6,879,000 |
goodwill | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 7,462,000 | 13,759,000 | 15,359,000 | 143,156,000 | 147,968,000 | 147,623,000 | 52,885,000 | 52,135,000 | 53,529,000 | 49,800,000 |
intangible assets | 359,659,000 | 368,419,000 | 377,398,000 | 386,954,000 | 395,731,000 | 404,729,000 | 414,809,000 | 424,552,000 | 470,668,000 | 482,350,000 | 493,324,000 | 505,223,000 | 516,039,000 | 1,038,724,000 | 1,055,601,000 | 666,523,000 | 681,369,000 | 695,193,000 | 248,794,000 | 257,848,000 | 271,042,000 | 191,650,000 |
operating lease assets | 4,687,000 | 5,122,000 | 5,830,000 | 6,225,000 | 6,631,000 | 6,506,000 | 9,779,000 | 10,366,000 | 12,462,000 | 13,353,000 | 14,298,000 | 15,238,000 | 16,063,000 | 17,308,000 | 16,304,000 | 18,342,000 | 18,738,000 | 17,186,000 | 16,938,000 | 17,669,000 | 18,060,000 | 14,961,000 |
deferred tax assets | 5,522,000 | 5,522,000 | 4,745,000 | 4,745,000 | 4,745,000 | 4,745,000 | 7,396,000 | 6,884,000 | 481,000 | 481,000 | 481,000 | 481,000 | ||||||||||
investment and other assets | 2,102,000 | 2,293,000 | 2,274,000 | 1,687,000 | 1,756,000 | 1,892,000 | 1,933,000 | 2,088,000 | 3,211,000 | 3,141,000 | 6,864,000 | 6,539,000 | 2,620,000 | 2,636,000 | 13,033,000 | 78,486,000 | 28,811,000 | 29,291,000 | 29,317,000 | 19,483,000 | 21,158,000 | |
total assets | 650,539,000 | 683,559,000 | 701,593,000 | 706,788,000 | 691,414,000 | 727,956,000 | 769,492,000 | 792,173,000 | 794,238,000 | 810,910,000 | 811,104,000 | 836,962,000 | 887,404,000 | 1,372,649,000 | 1,398,022,000 | 1,208,776,000 | 1,197,137,000 | 1,225,862,000 | 654,790,000 | 646,636,000 | 643,075,000 | 494,466,000 |
liabilities and stockholders' equity | ||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||
accounts payable | 24,050,000 | 10,928,000 | 26,649,000 | 24,245,000 | 19,197,000 | 23,690,000 | 16,849,000 | 24,437,000 | 19,099,000 | 23,038,000 | 17,637,000 | 41,364,000 | 32,828,000 | 37,549,000 | 19,075,000 | 25,735,000 | 22,500,000 | 16,915,000 | 10,897,000 | 9,881,000 | 10,283,000 | 4,422,000 |
accrued liabilities | 101,135,000 | 130,242,000 | 119,446,000 | 113,666,000 | 103,283,000 | 135,879,000 | 128,697,000 | 139,978,000 | 113,605,000 | 119,795,000 | 118,896,000 | 121,748,000 | 115,769,000 | 111,954,000 | 116,890,000 | 146,758,000 | 124,804,000 | 131,473,000 | 107,554,000 | 105,246,000 | 89,651,000 | 88,187,000 |
current portion of long-term debt | 18,750,000 | 15,000,000 | 11,250,000 | 43,358,000 | 37,339,000 | 27,339,000 | 38,566,000 | 38,566,000 | 35,811,000 | 27,848,000 | 19,584,000 | 11,320,000 | 41,320,000 | 33,056,000 | 31,302,000 | 22,547,000 | 20,292,000 | 18,038,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 |
other current liabilities | 4,160,000 | 4,210,000 | 4,407,000 | 4,411,000 | 4,359,000 | 3,917,000 | 3,918,000 | 3,829,000 | 4,806,000 | 4,816,000 | 4,726,000 | 4,672,000 | 4,273,000 | 3,843,000 | 3,491,000 | 3,833,000 | 3,926,000 | 3,558,000 | 2,993,000 | 3,964,000 | 10,161,000 | 3,926,000 |
total current liabilities | 148,095,000 | 160,380,000 | 161,752,000 | 185,680,000 | 174,751,000 | 210,398,000 | 211,492,000 | 231,463,000 | 173,321,000 | 175,497,000 | 160,843,000 | 179,104,000 | 196,063,000 | 304,017,000 | 288,373,000 | 198,873,000 | 171,522,000 | 180,859,000 | 160,705,000 | 158,186,000 | 149,027,000 | 122,589,000 |
long-term debt, less current portion | 253,326,000 | 278,951,000 | 311,334,000 | 297,880,000 | 308,593,000 | 308,288,000 | 345,021,000 | 344,716,000 | 355,430,000 | 366,998,000 | 375,033,000 | 374,568,000 | 404,265,000 | 385,010,000 | 393,102,000 | 351,433,000 | 348,039,000 | 339,644,000 | 162,437,000 | 166,084,000 | 169,731,000 | 173,378,000 |
deferred income tax liabilities | 568,000 | 433,000 | 786,000 | 651,000 | 607,000 | 564,000 | ||||||||||||||||
other long-term liabilities | 14,285,000 | 15,348,000 | 20,466,000 | 21,278,000 | 21,984,000 | 23,102,000 | 26,146,000 | 26,932,000 | 28,316,000 | 27,934,000 | 30,912,000 | 31,991,000 | 28,645,000 | 25,338,000 | 24,264,000 | 22,517,000 | 23,040,000 | 21,723,000 | 22,558,000 | 24,171,000 | 25,129,000 | 21,728,000 |
total liabilities | 416,274,000 | 455,112,000 | 494,338,000 | 505,489,000 | 505,935,000 | 542,352,000 | 582,659,000 | 603,111,000 | 576,806,000 | 589,792,000 | 584,648,000 | 603,621,000 | 647,042,000 | 1,032,317,000 | 1,018,876,000 | 688,586,000 | 675,219,000 | 692,073,000 | 424,293,000 | 427,272,000 | 422,793,000 | 350,306,000 |
commitments and contingencies | ||||||||||||||||||||||
stockholders’ equity | ||||||||||||||||||||||
preferred stock, 0.001 par value... | ||||||||||||||||||||||
class a common stock, 0.001 par value... | 68,000 | 67,000 | 67,000 | 67,000 | 66,000 | 66,000 | 65,000 | 65,000 | 64,000 | 63,000 | 63,000 | 63,000 | 63,000 | 62,000 | 64,000 | 64,000 | ||||||
class b common stock, 0.001 par value... | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | 16,000 | |
additional paid-in capital | 522,912,000 | 520,851,000 | 517,534,000 | 514,772,000 | 510,422,000 | 505,509,000 | 503,134,000 | 500,969,000 | 496,977,000 | 494,254,000 | 492,493,000 | 490,598,000 | 492,475,000 | 481,919,000 | 478,033,000 | 473,796,000 | 467,940,000 | 465,272,000 | 158,480,000 | 146,199,000 | 142,923,000 | |
accumulated deficit | -331,816,000 | -334,929,000 | -349,684,000 | -352,839,000 | -360,298,000 | -355,078,000 | -354,922,000 | -350,098,000 | -326,106,000 | -321,536,000 | -315,440,000 | -308,137,000 | -304,456,000 | -165,306,000 | -133,376,000 | -25,131,000 | -17,879,000 | -6,602,000 | -6,238,000 | -5,167,000 | -1,041,000 | -144,539,000 |
accumulated other comprehensive loss | -2,279,000 | -1,900,000 | -1,837,000 | -774,000 | -2,062,000 | |||||||||||||||||
total stockholders’ equity attributable to bioventus inc. | 188,901,000 | 184,105,000 | 166,096,000 | 161,242,000 | 148,144,000 | 147,940,000 | 148,738,000 | 150,935,000 | 171,276,000 | 173,591,000 | 177,529,000 | 183,195,000 | 188,511,000 | 316,581,000 | 343,397,000 | 447,981,000 | 449,776,000 | |||||
noncontrolling interest | 45,364,000 | 44,342,000 | 41,159,000 | 40,057,000 | 37,335,000 | 37,664,000 | 38,095,000 | 38,127,000 | 46,156,000 | 47,527,000 | 48,927,000 | 50,146,000 | 51,851,000 | 23,751,000 | 35,749,000 | 72,209,000 | 72,142,000 | 74,865,000 | 77,994,000 | 77,807,000 | 77,892,000 | 1,919,000 |
total stockholders’ equity | 234,265,000 | 228,447,000 | 207,255,000 | 201,299,000 | 185,479,000 | 185,604,000 | 186,833,000 | 189,062,000 | 217,432,000 | 221,118,000 | 226,456,000 | 233,341,000 | 240,362,000 | 340,332,000 | 379,146,000 | 520,190,000 | 521,918,000 | |||||
total liabilities and stockholders’ equity | 650,539,000 | 683,559,000 | 701,593,000 | 706,788,000 | 691,414,000 | 727,956,000 | 769,492,000 | 792,173,000 | 794,238,000 | 810,910,000 | 811,104,000 | 836,962,000 | 887,404,000 | 1,372,649,000 | 1,398,022,000 | 1,208,776,000 | 1,197,137,000 | |||||
current portion of contingent consideration | 10,573,000 | 19,573,000 | 19,228,000 | 18,745,000 | 13,386,000 | 13,220,000 | 13,057,000 | |||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||
contingent consideration | 18,445,000 | 18,150,000 | 17,860,000 | 17,958,000 | 17,718,000 | 84,682,000 | 81,914,000 | 16,871,000 | 16,598,000 | 16,329,000 | ||||||||||||
accumulated other comprehensive income | -2,573,000 | 445,000 | -17,000 | 325,000 | 794,000 | 397,000 | 655,000 | 413,000 | -110,000 | -1,340,000 | -764,000 | -363,000 | 179,000 | 204,000 | 468,000 | 451,000 | 1,607,000 | |||||
assets held for sale | 26,734,000 | 28,408,000 | 37,873,000 | |||||||||||||||||||
liabilities held for sale | 4,234,000 | 5,908,000 | 1,873,000 | |||||||||||||||||||
deferred income taxes | 1,294,000 | 1,213,000 | 351,000 | 154,001,000 | 159,300,000 | 98,892,000 | 116,020,000 | 133,518,000 | 47,687,000 | 48,410,000 | 48,963,000 | |||||||||||
current assets attributable to discontinued operations | ||||||||||||||||||||||
long-term assets attributable to discontinued operations | ||||||||||||||||||||||
current liabilities attributable to discontinued operations | ||||||||||||||||||||||
long-term liabilities attributable to discontinued operations | ||||||||||||||||||||||
restricted cash | 23,000 | 23,000 | 5,280,000 | 5,280,000 | 50,000,000 | 2,003,000 | 5,207,000 | |||||||||||||||
restricted cash, less current portion | 50,000,000 | 50,000,000 | ||||||||||||||||||||
accrued equity-based compensation | 10,875,000 | 10,875,000 | 10,875,000 | 10,875,000 | 11,054,000 | |||||||||||||||||
current portion of deferred consideration | 117,615,000 | 117,615,000 | ||||||||||||||||||||
deferred consideration, less current portion | 79,269,000 | |||||||||||||||||||||
deferred consideration | 71,923,000 | |||||||||||||||||||||
class a common stock | 62,000 | 59,000 | 41,000 | 41,000 | 41,000 | |||||||||||||||||
liabilities and stockholders' and members’ equity | ||||||||||||||||||||||
accrued equity-based compensation, less current portion | 29,249,000 | |||||||||||||||||||||
stockholders’ and members’ equity: | ||||||||||||||||||||||
members' equity | ||||||||||||||||||||||
total stockholders’ equity attributable to bioventus inc. and members’ equity | 458,924,000 | 152,503,000 | 141,557,000 | 142,390,000 | ||||||||||||||||||
total stockholders’ and members’ equity | 533,789,000 | 230,497,000 | 219,364,000 | 220,282,000 | ||||||||||||||||||
total liabilities and stockholders’ and members’ equity | 1,225,862,000 | 654,790,000 | 646,636,000 | 643,075,000 | ||||||||||||||||||
contingent consideration, less current portion | 30,906,000 | 30,421,000 | ||||||||||||||||||||
liabilities and stockholders’ and members’ equity | ||||||||||||||||||||||
long-term contingent consideration, less current portion | 29,943,000 | |||||||||||||||||||||
investments and other assets | 19,382,000 | |||||||||||||||||||||
liabilities and members’ equity | ||||||||||||||||||||||
deferred tax liability | 3,362,000 | |||||||||||||||||||||
members’ equity | 285,173,000 | |||||||||||||||||||||
equity attributable to unit holders | 142,241,000 | |||||||||||||||||||||
total members’ equity | 144,160,000 | |||||||||||||||||||||
total liabilities and members’ equity | 494,466,000 | |||||||||||||||||||||
balance at december 31, 2017 | 285,114,000 | |||||||||||||||||||||
profits interest compensation | 39,000 | |||||||||||||||||||||
distribution to members | ||||||||||||||||||||||
net income | ||||||||||||||||||||||
defined benefit plan adjustment | ||||||||||||||||||||||
translation adjustment | ||||||||||||||||||||||
balance at december 31, 2018 | 285,153,000 | |||||||||||||||||||||
profits interest forfeitures | -12,000 | |||||||||||||||||||||
acquisition of noncontrolling interest | ||||||||||||||||||||||
balance at december 31, 2019 | 285,147,000 | |||||||||||||||||||||
other equity compensation | 38,000 | |||||||||||||||||||||
debt conversion | ||||||||||||||||||||||
balance at december 31, 2020 | 285,173,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-28 | 2025-12-31 | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | 2024-06-29 | 2024-03-30 | 2023-12-31 | 2023-09-30 | 2023-07-01 | 2023-04-01 | 2022-12-31 | 2022-10-01 | 2022-07-02 | 2022-04-02 | 2021-12-31 | 2021-10-02 | 2021-07-03 | 2021-04-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities: | |||||||||||||||||||||
net income | 3,946,000 | 17,318,000 | 4,006,000 | -44,873,000 | -145,698,000 | -8,014,000 | -14,806,000 | -1,893,000 | -2,269,000 | -10,780,000 | 24,528,000 | ||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||
depreciation and amortization | 11,205,000 | 11,694,000 | 11,403,000 | 12,049,000 | 11,865,000 | 12,405,000 | 12,275,000 | 13,090,000 | 11,785,000 | 12,465,000 | 13,827,000 | 14,600,000 | 16,473,000 | 23,160,000 | 18,780,000 | 12,384,000 | 12,479,000 | 11,690,000 | 8,522,000 | 7,479,000 | 7,184,000 |
provision for credit losses | 230,000 | 101,000 | 193,000 | 650,000 | |||||||||||||||||
equity-based compensation | 3,264,000 | 3,440,000 | 3,176,000 | 3,643,000 | 2,414,000 | 2,064,000 | 3,672,000 | 2,591,000 | |||||||||||||
deferred income taxes | 135,000 | -1,131,000 | 135,000 | 44,000 | 43,000 | 3,215,000 | -511,000 | -8,179,000 | 81,000 | 1,163,000 | 0 | -876,000 | -2,664,000 | -5,638,000 | -19,456,000 | -10,680,000 | -17,018,000 | 83,000 | |||
loss on disposals | 0 | -1,000 | 1,000 | 81,000 | 1,196,000 | ||||||||||||||||
unrealized loss on foreign currency fluctuations | 54,000 | -123,000 | -242,000 | -126,000 | -669,000 | 159,000 | 377,000 | -732,000 | 796,000 | -1,543,000 | |||||||||||
other | 275,000 | 155,000 | 243,000 | 382,000 | 381,000 | 1,251,000 | 598,000 | 380,000 | 581,000 | 306,000 | 262,000 | 915,000 | 224,000 | 222,000 | -1,262,000 | 1,181,000 | 247,000 | 1,132,000 | 183,000 | -768,000 | 513,000 |
changes in operating assets and liabilities: | |||||||||||||||||||||
accounts receivable | 7,318,000 | 1,885,000 | 1,824,000 | -13,629,000 | 9,004,000 | -5,792,000 | 17,059,000 | -19,975,000 | -1,958,000 | -9,192,000 | 7,918,000 | -1,833,000 | 13,162,000 | -5,182,000 | 8,317,000 | -25,573,000 | 4,416,000 | -6,903,000 | -3,779,000 | -11,982,000 | 2,612,000 |
inventories | -2,648,000 | 291,000 | -2,809,000 | -1,881,000 | -2,515,000 | -4,289,000 | -4,070,000 | -1,049,000 | -7,780,000 | -5,294,000 | -9,997,000 | -6,007,000 | -2,940,000 | 326,000 | 1,687,000 | -2,417,000 | |||||
accounts payable and accrued expenses | -15,367,000 | -4,444,000 | 7,311,000 | 16,423,000 | -39,104,000 | 16,622,000 | -21,328,000 | 29,884,000 | -7,332,000 | 5,792,000 | -25,832,000 | 12,434,000 | 2,331,000 | 21,860,000 | -28,694,000 | 25,662,000 | -7,915,000 | 10,964,000 | 4,330,000 | 16,990,000 | -14,073,000 |
other current and noncurrent assets and liabilities | 522,000 | -4,202,000 | 1,251,000 | 492,000 | 780,000 | -7,377,000 | 6,326,000 | -77,000 | -1,397,000 | -2,757,000 | 2,750,000 | 166,000 | -2,129,000 | 9,412,000 | -2,032,000 | ||||||
net cash from operating activities | 8,934,000 | 37,968,000 | 30,098,000 | 25,938,000 | -19,331,000 | 19,322,000 | 10,316,000 | 15,162,000 | -6,005,000 | 10,374,000 | -8,315,000 | 10,795,000 | 2,490,000 | 5,244,000 | -701,000 | 2,939,000 | -21,019,000 | 13,117,000 | 10,587,000 | 17,329,000 | -18,042,000 |
capital expenditures | -40,000 | -558,000 | -451,000 | -627,000 | -686,000 | -645,000 | -156,000 | -90,000 | -73,000 | -362,000 | -1,700,000 | -1,397,000 | -4,254,000 | -446,000 | -2,039,000 | -2,884,000 | -2,719,000 | -2,009,000 | -1,272,000 | -1,213,000 | |
free cash flows | 8,894,000 | 37,410,000 | 29,647,000 | 25,311,000 | -20,017,000 | 18,677,000 | 10,160,000 | 15,072,000 | -6,078,000 | 10,012,000 | -10,015,000 | 9,398,000 | 990,000 | -1,147,000 | 900,000 | -23,903,000 | 10,398,000 | 8,578,000 | 16,057,000 | -19,255,000 | |
investing activities: | |||||||||||||||||||||
purchase of property and equipment | -574,000 | -580,000 | -473,000 | -683,000 | -826,000 | -574,000 | -64,000 | -77,000 | -291,000 | -369,000 | -2,036,000 | -1,397,000 | -3,560,000 | -3,403,000 | -1,649,000 | -2,030,000 | -2,960,000 | -2,802,000 | -1,926,000 | -1,272,000 | -1,370,000 |
net cash from investing activities | -574,000 | -580,000 | -473,000 | -1,369,000 | -826,000 | 24,104,000 | -64,000 | -77,000 | -1,000,000 | -591,000 | -2,036,000 | 33,500,000 | -15,066,000 | -3,403,000 | -56,334,000 | -52,025,000 | -4,674,000 | -221,278,000 | -13,186,000 | -2,648,000 | -46,648,000 |
financing activities: | |||||||||||||||||||||
proceeds from issuance of class a common stock | 120,000 | 96,000 | 1,317,000 | 150,000 | 553,000 | 609,000 | 177,000 | ||||||||||||||
tax withholdings on equity-based compensation | -1,044,000 | 0 | 0 | 0 | 0 | -3,352,000 | |||||||||||||||
payment of contingent consideration | 0 | 0 | -10,771,000 | -9,000,000 | |||||||||||||||||
borrowing on revolver | 0 | 30,000,000 | 0 | 15,000,000 | 0 | 15,000,000 | 0 | 49,000,000 | 0 | 0 | 10,000,000 | 15,000,000 | |||||||||
payment on revolver | -25,000,000 | -10,000,000 | -5,000,000 | -5,000,000 | 0 | -7,000,000 | -22,000,000 | -20,000,000 | 0 | ||||||||||||
payments on long-term debt | -22,000,000 | -33,264,000 | 0 | -8,264,000 | -3,056,000 | 0 | 0 | -6,510,000 | -4,509,000 | -4,510,000 | -4,509,000 | -80,000,000 | -3,750,000 | -3,750,000 | -3,750,000 | ||||||
net cash from financing activities | -23,144,000 | -28,447,000 | -19,977,000 | -14,663,000 | 947,000 | -42,855,000 | 362,000 | -7,845,000 | -4,242,000 | -14,000 | 8,229,000 | -62,248,000 | 27,380,000 | -5,438,000 | 50,654,000 | 7,655,000 | 9,205,000 | 176,308,000 | -4,346,000 | -6,117,000 | 107,526,000 |
effect of exchange rate changes on cash | -608,000 | 133,000 | -394,000 | 202,000 | 430,000 | -2,063,000 | 466,000 | -419,000 | -544,000 | 368,000 | -440,000 | 240,000 | 461,000 | 1,052,000 | -238,000 | -222,000 | -71,000 | 149,000 | -206,000 | 50,000 | -221,000 |
net change in cash and cash equivalents | -15,392,000 | 9,074,000 | 9,254,000 | 10,108,000 | -18,780,000 | ||||||||||||||||
cash and cash equivalents at the beginning of the period | 51,238,000 | 0 | 0 | 0 | 41,582,000 | ||||||||||||||||
cash and cash equivalents at the end of the period | 35,846,000 | 9,074,000 | 9,254,000 | 10,108,000 | 22,802,000 | ||||||||||||||||
supplemental disclosure of noncash investing and financing activities: | |||||||||||||||||||||
accounts payable for purchase of property, plant and equipment | 534,000 | 22,000 | 22,000 | 56,000 | 140,000 | -71,000 | -92,000 | -13,000 | 218,000 | 7,000 | 336,000 | -851,000 | 1,203,000 | -9,000 | 76,000 | 83,000 | -83,000 | ||||
less: loss from discontinued operations, net of tax | 0 | 0 | 0 | -74,429,000 | |||||||||||||||||
income from continuing operations | |||||||||||||||||||||
provision for expected credit losses | 439,000 | -976,000 | -408,000 | -1,335,000 | -439,000 | 1,079,000 | 1,152,000 | 191,000 | |||||||||||||
change in fair value of contingent consideration | 345,000 | 483,000 | 300,000 | 295,000 | 290,000 | -98,000 | 240,000 | 287,000 | 2,768,000 | 3,142,000 | 273,000 | 269,000 | -463,000 | 651,000 | |||||||
impairments of assets | |||||||||||||||||||||
loss on extinguishment | 0 | ||||||||||||||||||||
inventory | -3,051,000 | ||||||||||||||||||||
net cash from operating activities - continuing operations | 19,322,000 | 10,316,000 | 15,162,000 | -6,005,000 | 10,374,000 | -8,315,000 | 10,795,000 | 4,659,000 | 13,117,000 | ||||||||||||
net cash from operating activities - discontinued operations | 0 | 0 | 0 | -2,169,000 | |||||||||||||||||
(settlement) proceeds from the sale of a business | |||||||||||||||||||||
investments and acquisition of distribution rights | 0 | 0 | 0 | -709,000 | 0 | 0 | 0 | -1,478,000 | |||||||||||||
net cash from investing activities - continuing operations | 24,104,000 | -64,000 | -77,000 | -1,000,000 | -591,000 | -2,036,000 | 33,500,000 | -3,560,000 | -221,278,000 | ||||||||||||
net cash from investing activities - discontinued operations | 0 | 0 | 0 | -11,506,000 | |||||||||||||||||
proceeds from issuance of class a and b common stock | 139,000 | 84,000 | 1,083,000 | 482,000 | 2,177,000 | 2,080,000 | 886,000 | 417,000 | |||||||||||||
receipt of deferred consideration | |||||||||||||||||||||
proceeds from the issuance of long-term debt, net of discount | 0 | ||||||||||||||||||||
payments on the extinguishment of long-term debt | 0 | ||||||||||||||||||||
debt financing costs | |||||||||||||||||||||
supplemental disclosure of noncash investing and financing activities | |||||||||||||||||||||
accrued liabilities for distribution rights and member distributions | |||||||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||
impairment of assets | 2,031,000 | 0 | 0 | 78,615,000 | |||||||||||||||||
unrealized gain on foreign currency fluctuations | |||||||||||||||||||||
settlement from the sale of a business | 0 | ||||||||||||||||||||
debt refinancing costs | 0 | 0 | -1,180,000 | 0 | -1,993,000 | -1,668,000 | |||||||||||||||
scheduled payments on long-term debt | |||||||||||||||||||||
net loss | -3,322,000 | -318,000 | -5,421,000 | -32,112,000 | -5,982,000 | -8,791,000 | -4,731,000 | -174,447,000 | |||||||||||||
loss from continuing operations | -318,000 | -5,421,000 | -32,112,000 | -5,982,000 | -8,791,000 | -4,731,000 | -100,018,000 | ||||||||||||||
equity-based compensation from 2021 stock incentive plan | 3,432,000 | 4,648,000 | 4,616,000 | 4,889,000 | 6,109,000 | 5,938,000 | 5,853,000 | 1,944,000 | |||||||||||||
change in fair value of interest rate swap | 22,000 | -2,222,000 | -272,000 | -3,924,000 | -1,339,000 | -81,000 | 255,000 | -1,565,000 | |||||||||||||
proceeds from sale of a business | -222,000 | 0 | |||||||||||||||||||
proceeds from the issuance of long-term debt, net of issuance costs | 0 | ||||||||||||||||||||
net change in cash, cash equivalents and restricted cash | -1,492,000 | 11,080,000 | 6,821,000 | -11,791,000 | 10,137,000 | -2,562,000 | -17,713,000 | 15,265,000 | -2,545,000 | -6,619,000 | -41,653,000 | -16,559,000 | -31,704,000 | -7,151,000 | 8,614,000 | 42,615,000 | |||||
cash, cash equivalents and restricted cash at the beginning of the period | 0 | 0 | 0 | 36,964,000 | 0 | 0 | 0 | 31,837,000 | 0 | 0 | 0 | 99,213,000 | 0 | 0 | 0 | 86,839,000 | |||||
cash, cash equivalents and restricted cash at the end of the period | -1,492,000 | 11,080,000 | 6,821,000 | 25,173,000 | 10,137,000 | -2,562,000 | -17,713,000 | 47,102,000 | -2,545,000 | -6,619,000 | -41,653,000 | 82,654,000 | -31,704,000 | -7,151,000 | 8,614,000 | 129,454,000 | |||||
benefit for expected credit losses | |||||||||||||||||||||
accrued liabilities for intellectual property | 0 | ||||||||||||||||||||
profits interest plan, liability-classified and other equity awards compensation | 0 | 0 | 0 | -24,356,000 | |||||||||||||||||
change in fair value of equity participation rights | |||||||||||||||||||||
loss on debt retirement and modification | |||||||||||||||||||||
acquisitions, net of cash acquired | 5,000 | -236,000 | |||||||||||||||||||
proceeds from issuance of class a common stock sold in initial public offering, net of underwriting discounts and offering costs | 0 | 0 | -2,633,000 | 110,410,000 | |||||||||||||||||
registration fees for class a common stock to purchase misonix | |||||||||||||||||||||
equity based compensation | 1,833,000 | -2,732,000 | 1,846,000 | ||||||||||||||||||
loss on disposal of a business | |||||||||||||||||||||
investment held in trust for the acquisition of cartiheal | |||||||||||||||||||||
foreign currency fluctuations | 747,000 | ||||||||||||||||||||
impairment of goodwill and asset impairment charges | |||||||||||||||||||||
impairments related to variable interest entity | 0 | 0 | |||||||||||||||||||
revaluation gain on previously held equity interest in cartiheal | 0 | ||||||||||||||||||||
distributions to members | -184,000 | ||||||||||||||||||||
accrued liabilities for distribution rights | |||||||||||||||||||||
accrued member distributions | 3,058,000 | -182,000 | -267,000 | 572,000 | |||||||||||||||||
debt conversion | |||||||||||||||||||||
provision (recovery) for expected credit losses | 1,369,000 | ||||||||||||||||||||
impairment of goodwill | |||||||||||||||||||||
acquisition of cartiheal, net of cash acquired | |||||||||||||||||||||
acquisition of bioness, net of cash acquired | |||||||||||||||||||||
refunds from members | 854,000 | ||||||||||||||||||||
other current assets and liabilities | -1,134,000 | -712,000 | |||||||||||||||||||
net loss from discontinued operations | |||||||||||||||||||||
net income from continuing operations | |||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities from continuing operations: | |||||||||||||||||||||
payment of contingent consideration in excess of amount established in purchase accounting | |||||||||||||||||||||
change in fair value of equity participation rights unit | 0 | -2,774,000 | |||||||||||||||||||
other assets and liabilities | -9,157,000 | ||||||||||||||||||||
registration fees for the class a common stock to purchase misonix | |||||||||||||||||||||
(recovery) provision for expected credit losses | 221,000 | ||||||||||||||||||||
purchase of bioness, inc., net of cash acquired | |||||||||||||||||||||
investments | |||||||||||||||||||||
purchase of bioness, inc, net of cash acquired | 1,000 | -45,791,000 | |||||||||||||||||||
refunds (distributions) - members | |||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities | |||||||||||||||||||||
foreign currency adjustments | 256,000 | ||||||||||||||||||||
amortization of debt discount and capitalized loan fees | 136,000 | ||||||||||||||||||||
proceeds from issuance of class b common stock | 16,000 | ||||||||||||||||||||
accounts payable for the purchase of property, plant and equipment | 157,000 | ||||||||||||||||||||
loss on impairment of intangible assets | |||||||||||||||||||||
net cash from operating activities from continuing operations | |||||||||||||||||||||
net cash from operating activities of discontinued operations | |||||||||||||||||||||
investment and acquisition of distribution rights | |||||||||||||||||||||
acquisition of vie | |||||||||||||||||||||
net cash from investing activities from continuing operations | |||||||||||||||||||||
net cash from investing activities from discontinued operations | |||||||||||||||||||||
other financing activities | |||||||||||||||||||||
distribution to members | |||||||||||||||||||||
supplemental disclosure of cash flow information | |||||||||||||||||||||
cash paid for income taxes | |||||||||||||||||||||
cash paid for interest | |||||||||||||||||||||
accounts payable for purchase of property and equipment | |||||||||||||||||||||
accrued member distribution |